8.02
+0.08(+1.01%)
Currency In USD
Address
60 Binney Street
Cambridge, MA 02142
United States of America
Phone
339 499 9300
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
248
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Mr. Andrew Obenshain | President, Chief Executive Officer & Director | 746,605 | 1975 |
| Mr. Thomas J. Klima | Chief Commercial & Operating Officer | 527,924 | 1972 |
| Mr. Joseph D. Vittiglio Esq., J.D. | Chief Legal & Business Officer and Secretary | 574,493 | 1972 |
| Dr. Richard A. Colvin M.D., Ph.D. | Chief Medical Officer | 691,403 | 1967 |
| Mr. Oliver James Sterling III | Chief Financial Officer & Principal Accounting Officer | 0 | N/A |
| Ms. Andrea Walton | Chief People Officer | 0 | N/A |
| Mr. Kasra Kasraian | Senior Vice President of Quality, Regulatory & CMC Sciences | 0 | N/A |
| Mr. Scott Shoemaker | Senior Vice President of Technical Operations | 0 | N/A |
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.